Deficiency of C3a Receptor Attenuates the Development of Diabetic Nephropathy

Overview

Journal BMJ Open Diabetes Res Care

Specialty Endocrinology

Date 2019 Dec 5

PMID 31798904

Citations 14

Authors

Xiao-Qian Li

Dong-Yuan Chang

Min Chen

Ming-Hui Zhao

Affiliations

Soon will be listed here.

Abstract

Objective: Diabetic nephropathy (DN) is the leading cause of chronic kidney disease and end-stage renal disease. Emerging evidence suggests that complement activation is involved in the pathogenesis of DN. The aim of this study was to investigate the pathogenic role of C3a and C3a receptor (C3aR) in DN.

Research Design And Methods: The expression of C3aR was examined in the renal specimen of patients with DN. Using a C3aR gene knockout mice (), we evaluated kidney injury in diabetic mice. The mouse gene expression microarray was performed to further explore the pathogenic role of C3aR. Then the underlying mechanism was investigated in vitro with macrophage treated with C3a.

Results: Compared with normal controls, the renal expression of C3aR was significantly increased in patients with DN. diabetic mice developed less severe diabetic renal damage compared with wild-type (WT) diabetic mice, exhibiting significantly lower level of albuminuria and milder renal pathological injury. Microarray profiling uncovered significantly suppressed inflammatory responses and T-cell adaptive immunity in diabetic mice compared with WT diabetic mice, and this result was further verified by immunohistochemical staining of renal CD4+, CD8+ T cells and macrophage infiltration. In vitro study demonstrated C3a can enhance macrophage-secreted cytokines which could induce inflammatory responses and differentiation of T-cell lineage.

Conclusions: C3aR deficiency could attenuate diabetic renal damage through suppressing inflammatory responses and T-cell adaptive immunity, possibly by influencing macrophage-secreted cytokines. Thus, C3aR may be a promising therapeutic target for DN.

Citing Articles

Shared signaling pathways and comprehensive therapeutic approaches among diabetes complications.

Ebrahimi M, Ahmadieh H, Kanavi M, Safi S, Alipour-Parsa S, Advani S Front Med (Lausanne). 2025; 11:1497750.

PMID: 39845838 PMC: 11750824. DOI: 10.3389/fmed.2024.1497750.

Complement classical and alternative pathway activation contributes to diabetic kidney disease progression: a glomerular proteomics on kidney biopsies.

Yang Y, Zhang Y, Li Y, Zhou X, Honda K, Kang D Sci Rep. 2025; 15(1):495.

PMID: 39753879 PMC: 11698715. DOI: 10.1038/s41598-024-84900-4.

Complement anaphylatoxins: Potential therapeutic target for diabetic kidney disease.

Ma J, Yiu W, Tang S Diabet Med. 2024; 42(2):e15427.

PMID: 39189098 PMC: 11733663. DOI: 10.1111/dme.15427.

Association between serum complements and kidney function in patients with diabetic kidney disease.

Liu M, Li J, Wang Y, Meng Y, Zheng G, Cai Z Front Endocrinol (Lausanne). 2023; 14:1195966.

PMID: 38047115 PMC: 10690951. DOI: 10.3389/fendo.2023.1195966.

Sex-Specific Immune Responses to Seasonal Influenza Vaccination in Diabetic Individuals: Implications for Vaccine Efficacy.

Sengupta A, Al-Otaibi N, Hinkula J J Immunol Res. 2023; 2023:3111351.

PMID: 37881338 PMC: 10597737. DOI: 10.1155/2023/3111351.

References

Ho I, Miaw S . Regulation of IL-4 Expression in Immunity and Diseases. Adv Exp Med Biol. 2016; 941:31-77. DOI: 10.1007/978-94-024-0921-5_3. View

Zhu J, Paul W . Peripheral CD4+ T-cell differentiation regulated by networks of cytokines and transcription factors. Immunol Rev. 2010; 238(1):247-62. PMC: 2975272. DOI: 10.1111/j.1600-065X.2010.00951.x. View

Wu C, Sytwu H, Lu K, Lin Y . Role of T cells in type 2 diabetic nephropathy. Exp Diabetes Res. 2011; 2011:514738. PMC: 3199084. DOI: 10.1155/2011/514738. View

Klos A, Tenner A, Johswich K, Ager R, Reis E, Kohl J . The role of the anaphylatoxins in health and disease. Mol Immunol. 2009; 46(14):2753-66. PMC: 2725201. DOI: 10.1016/j.molimm.2009.04.027. View

Furman B . Streptozotocin-Induced Diabetic Models in Mice and Rats. Curr Protoc Pharmacol. 2015; 70:5.47.1-5.47.20. DOI: 10.1002/0471141755.ph0547s70. View

Fortpied J, Vertommen D, Van Schaftingen E . Binding of mannose-binding lectin to fructosamines: a potential link between hyperglycaemia and complement activation in diabetes. Diabetes Metab Res Rev. 2010; 26(4):254-60. DOI: 10.1002/dmrr.1079. View

Wada J, Makino H . Innate immunity in diabetes and diabetic nephropathy. Nat Rev Nephrol. 2015; 12(1):13-26. DOI: 10.1038/nrneph.2015.175. View

Navarro-Gonzalez J, Mora-Fernandez C, de Fuentes M, Garcia-Perez J . Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol. 2011; 7(6):327-40. DOI: 10.1038/nrneph.2011.51. View

Acosta J, Hettinga J, Fluckiger R, Krumrei N, Goldfine A, Angarita L . Molecular basis for a link between complement and the vascular complications of diabetes. Proc Natl Acad Sci U S A. 2000; 97(10):5450-5. PMC: 25849. DOI: 10.1073/pnas.97.10.5450. View

10.

Liszewski M, Kolev M, Le Friec G, Leung M, Bertram P, Fara A . Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation. Immunity. 2013; 39(6):1143-57. PMC: 3865363. DOI: 10.1016/j.immuni.2013.10.018. View

11.

Zheng Z, Zheng F . Immune Cells and Inflammation in Diabetic Nephropathy. J Diabetes Res. 2016; 2016:1841690. PMC: 4707326. DOI: 10.1155/2016/1841690. View

12.

Flyvbjerg A . The role of the complement system in diabetic nephropathy. Nat Rev Nephrol. 2017; 13(5):311-318. DOI: 10.1038/nrneph.2017.31. View

13.

Tesch G . Diabetic nephropathy - is this an immune disorder?. Clin Sci (Lond). 2017; 131(16):2183-2199. DOI: 10.1042/CS20160636. View

14.

Tesch G . Role of macrophages in complications of type 2 diabetes. Clin Exp Pharmacol Physiol. 2007; 34(10):1016-9. DOI: 10.1111/j.1440-1681.2007.04729.x. View

15.

Braun M, Reins R, Li T, Hollmann T, Dutta R, Rick W . Renal expression of the C3a receptor and functional responses of primary human proximal tubular epithelial cells. J Immunol. 2004; 173(6):4190-6. DOI: 10.4049/jimmunol.173.6.4190. View

16.

Woroniecka K, Park A, Mohtat D, Thomas D, Pullman J, Susztak K . Transcriptome analysis of human diabetic kidney disease. Diabetes. 2011; 60(9):2354-69. PMC: 3161334. DOI: 10.2337/db10-1181. View

17.

Wehner H, Hohn D, HUBER H, Walzer P . Glomerular changes in mice with spontaneous hereditary diabetes. Lab Invest. 1972; 27(3):331-40. View

18.

Rasmussen K, Nordestgaard B, Nielsen S . Complement C3 and Risk of Diabetic Microvascular Disease: A Cohort Study of 95202 Individuals from the General Population. Clin Chem. 2018; 64(7):1113-1124. DOI: 10.1373/clinchem.2018.287581. View

19.

Li X, Chang D, Chen M, Zhao M . Complement activation in patients with diabetic nephropathy. Diabetes Metab. 2018; 45(3):248-253. DOI: 10.1016/j.diabet.2018.04.001. View

20.

Ricklin D, Reis E, Lambris J . Complement in disease: a defence system turning offensive. Nat Rev Nephrol. 2016; 12(7):383-401. PMC: 4974115. DOI: 10.1038/nrneph.2016.70. View